enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Treatment-resistant depression - Wikipedia

   en.wikipedia.org/wiki/Treatment-resistant_depression

   Ketamine has been tested as a rapid-acting antidepressant [22] for treatment-resistant depression in bipolar disorder, and major depressive disorder. [23] Spravato, a nasal spray form of esketamine, was approved by the FDA in 2019 for use in treatment-resistant depression when combined with an oral antidepressant. [24] [25]

3. Breakthrough antidepressants with fewer side effects could ...

   www.aol.com/finance/breakthrough-antidepressants...

   The FDA approved Johnson & Johnson’s drug for treatment-resistant depression in 2019. Esketamine is derived from a pediatric anesthetic called ketamine. Through research pioneered at Yale ...

4. Vagus nerve stimulation may relieve treatment-resistant ... - AOL

   www.aol.com/news/those-treatment-resistant...

   Vagus nerve stimulation therapy improved the symptoms of treatment-resistant depression for nearly 500 participants in a major clinical trial. ... knowing all other options had failed, Nick’s ...

5. Nerve-stimulation therapy can get people out of severe depression

   www.aol.com/nerve-stimulation-therapy-people...

   Nerve-stimulation therapy can greatly improve symptoms of severe, treatment-resistant depression, a new clinical trial shows.. The results of the trial, published last month in a pair of studies ...

6. Ketamine-assisted psychotherapy - Wikipedia

   en.wikipedia.org/wiki/Ketamine-assisted...

   Ketamine-assisted psychotherapy (KAP) is the use of prescribed doses of ketamine as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety, obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. [1]

7. List of investigational antidepressants - Wikipedia

   en.wikipedia.org/wiki/List_of_investigational...

   This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. Specific indications include major depressive disorder, treatment-resistant depression, dysthymia, bipolar depression, and postpartum depression, among others.